Transcendent Capital Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Transcendent Capital Group’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-15,152	Closed	-$1.85M	–	125
2025 Q4	$1.85M	Sell	15,152 -4,797	-24%	-$550K	0.84%	41
2025 Q3	$2M	Buy	+19,949	New	+$1.8M	0.89%	38
2024 Q4	–	Sell	-120	Closed	-$11.9K	–	492
2024 Q3	$11.9K	Sell	120 -17,544	-99%	-$1.72M	0.01%	344
2024 Q2	$1.64M	Buy	+17,664	New	+$1.58M	0.94%	32

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Transcendent Capital Group's XBI Position: Q1 2026 in Review

Transcendent Capital Group sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2026, closing a stake of 15,152 shares — an estimated $1.85M sold.

Transcendent Capital Group first reported a position in XBI in Q2 2024 and held it in 4 quarters. The position peaked at $2M in Q3 2025. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Transcendent Capital Group reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2026 after selling out during the quarter.
Transcendent Capital Group sold 15,152 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $1.85M.
Transcendent Capital Group first reported a position in State Street SPDR S&P Biotech ETF in Q2 2024 and held it in 4 quarters.
Transcendent Capital Group's State Street SPDR S&P Biotech ETF position peaked at $2M in Q3 2025.
813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Transcendent Capital Group's 13F filing for Q1 2026, filed 27 Apr 2026.